Natalizumab is associated with no evidence of disease activity and improved cognitive function and health-related quality of life in anti-JC virus seronegative patients with early relapsing-remitting multiple sclerosis: a 3-year analysis of STRIVE
MULTIPLE SCLEROSIS JOURNAL(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要